6 June 2016 NOT for RELEASE, PUBLICATION OR DISTRIBUTION

Total Page:16

File Type:pdf, Size:1020Kb

6 June 2016 NOT for RELEASE, PUBLICATION OR DISTRIBUTION 6 June 2016 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO DISTRIBUTE THIS ANNOUNCEMENT This announcement is an advertisement and not a prospectus or admission document and does not constitute an offer to sell or a solicitation of an offer to buy securities in any jurisdiction in which such offer or solicitation is unlawful. Investors should not subscribe for or purchase any transferable securities referred to in this announcement except on the basis of the information in the admission document dated 3 June 2016 (the (Admission Document) published by Mereo BioPharma Group plc (Mereo or the Company and, together with its subsidiaries, the Group) in connection with the admission of its ordinary shares (Ordinary Shares) to trading on the AIM market of the London Stock Exchange plc (Admission). Copies of the Admission Document will be available for inspection for a period of 12 months from the date of Admission at the offices of Proskauer Rose (UK) LLP. This document is only being distributed to and is only directed at (i) persons who are outside the United Kingdom or (ii) to investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the Order) or (iii) high net worth companies, and other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons in (i), (ii) and (iii) above together being referred to as "relevant persons"). The Ordinary Shares are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such Ordinary Shares will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents. In any EEA Member State that has implemented the Prospectus Directive, this communication is only addressed to and is only directed at qualified investors in that Member State within the meaning of the Prospectus Directive, and such other persons as this document may be addressed on legal grounds, and no person that is not a relevant person or qualified investor may act or rely on this document or any of its contents. The expression "Prospectus Directive" means Directive 2003/71/EC (and amendments thereto, including Directive 2010/73/EU to the extent implemented in any relevant Member State) and includes any relevant implementing measure in the relevant Member State. Mereo BioPharma Group plc Proposed Admission to trading on AIM and a further Capital Raise of £14.8m A clinical stage, UK-based, biopharmaceutical company founded in March 2015 with a focus on rare and specialty disease areas Initial portfolio of three Phase 2 product candidates from Novartis; the Company has already commenced two new Phase 2 clinical studies in 2016 and intends to commence registration studies with lead product candidate BPS-804 during H2 2016 Leveraging an early mover advantage in a new model for pharmaceutical development coupled with a flexible strategy to realising downstream value Highly experienced management team building a scalable business and backed by leading institutional shareholders The proceeds of the Private Placement and convertible loan (together, the Capital Raise) will provide additional funds to the £76.5 million committed in July 2015. Together this will allow the Group to bring its existing product candidates through significant potential value inflection points Mereo, a UK-based specialty biopharmaceutical company, is pleased to announce that it expects Admission of its Ordinary Shares to trading on AIM to take effect on 9 June 2016. The Company has also completed a supplementary Capital Raise with total gross proceeds of £14.8 million comprised of a private placement of its Ordinary Shares raising gross proceeds of £11.35 million at a price of £2.21 per Ordinary Share (the Private Placement) and a cash investment by existing shareholder Novartis by way of a convertible loan, in the amount of £3.46 million. The Capital Raise follows a private placement in July 2015 when the Company received £20 million, with a further £56.5 million committed. Trading in Mereo’s Ordinary Shares on the AIM market of the London Stock Exchange is expected to commence at 8:00am on 9 June 2016 under the ticker symbol “MPH” with ISIN GB00BZ4G2K23. The Group’s focus is on the development of innovative medicines that aim to address unmet medical needs in rare and specialty disease areas and improve patient quality of life. The Group seeks to selectively acquire clinical-stage product candidates with demonstrated clinically meaningful data from large pharmaceutical companies and to further develop these product candidates to subsequent key value inflection points or to commercialisation. The Group is an early adopter of a novel business model that aligns its interests with those of large pharmaceutical companies. In July 2015, the Group acquired three Phase 2 product candidates which comprise its initial portfolio from Novartis, a global pharmaceutical company with a history of robust product development and a reputation for product study data quality and secured £76.5 million (US$118 million), gross proceeds, by way of an initial private placement of its Ordinary Shares. Since that time the Company has initiated a Phase 2 study and a Phase 2b study in relation to two of the product candidates in 2016 and intends to commence registration studies during H2 2016 for the third product candidate. In the near term, the Group aims to further develop this portfolio, while in the medium to long term the Group intends to build a broader pipeline of product candidates which fulfil Mereo’s selection criteria. Commenting on today’s announcement, Denise Scots-Knight, Chief Executive Officer of Mereo, said: “We are very excited to be joining AIM, allowing the Company to take the next logical step towards realising our vision of becoming a leading speciality biopharma company. On Admission we will have raised over £90 million from institutional investors since July 2015 which has allowed us to acquire three carefully selected clinical stage pipeline assets from Novartis and subsequently advance these product candidates, including through the initiation of two new clinical studies. Our strategy is to build, over time, a diverse portfolio, and having publically-traded shares, will provide additional flexibility to secure the next product candidates which are likely to be primarily sourced from large pharmaceutical companies. Such product candidates are expected to have compelling market potential, robust preclinical, clinical and manufacturing data packages, and a clear path to a significant value inflection point. We also aim to retain optionality on how we realise value from each asset downstream.” “We would like to thank our existing and new shareholders who have participated in the supplemental Capital Raise we have announced today. We now have sufficient funding in the near to medium term to significantly advance the clinical development for the three initial product candidates in our pipeline to potential significant value inflection points.” “We are well positioned to leverage our early mover advantage in a novel business model that aligns our interests with those of large pharmaceutical companies for drug development and we are confident that we have the right ingredients and experience to build a scalable and sustainable specialty pharmaceutical business” Admission Highlights Admission to the AIM market of the London Stock Exchange and the commencement of trading in the Ordinary Shares is expected to take place at 8:00am on 9 June 2016 under the ticker “MPH” The Company has completed a Capital Raise of £14.8 million comprised of a Private Placement of its Ordinary Shares and a cash investment by Novartis by way of a convertible loan The Capital Raise follows a private placement in July 2015 when the Company raised £20 million, with a further £56.5 million committed The Private Placement announced today was completed at a price of £2.21 per Ordinary Share The Directors believe the Capital Raise will provide additional funds to allow the Group to bring its product candidates to the next stage of development RBC Capital Markets is acting as Global Coordinator, Private Placement Agent and Broker to the Company and Cantor Fitzgerald Europe is acting as Nominated Adviser, Private Placement Agent and Broker. Evercore is acting as Financial Adviser to the Company. Key Strengths of the Company Product candidates’ selection based on strong scientific rationale and a clear path to significant value generating inflection points- clinical progress achieved since the private placement in July 2015: All three product candidates in the existing portfolio have demonstrated proof of concept in their targeted indications and have been well tolerated in studies to date Diversified investment risk as each of the Group’s initial product candidates has different mechanisms of action, regulatory frameworks and pricing and reimbursement considerations o BPS-804 is being developed for the prevention of fractures resulting from osteogenesis imperfecta (brittle bone disease) . Recurrent fractures are the key clinical issue faced by these patients. In March 2016 the Company announced that the U.S. Food and Drug Administration (FDA) has granted BPS-804 orphan drug designation and in May 2016 received a positive opinion of the COMP with respect to orphan drug designation for BPS-804 in the European Union . The Company intends to commence a registration trial for BPS-804 in H2 2016. o BCT-197, is being developed to treat inflammation in patients with an acute exacerbation of chronic obstructive pulmonary disease (AECOPD) . The treatment aim is to ultimately reduce an AECOPD patient’s hospital stay whereas current treatments for AECOPD are supportive therapies that do not treat the underlying disease .
Recommended publications
  • PULSE: Speaker Biographies March 2019
    PULSE: Speaker Biographies March 2019 Supported by @BIA_UK www.bioindustry.org In order of appearance: Dr Barbara Domayne-Hayman Entrepreneur-in-residence, Francis Crick Institute, CBO, Autifony Therapeutics Ltd and formerly Chairman, Puridify Barbara has worked on the commercial side of life sciences for thirty years, first in a large organisation (ICI/Zeneca/AstraZeneca), before transitioning to the entrepreneurial world of biotech. Barbara joined the Francis Crick Institute in January 2018 as Entrepreneur-in- residence. She is also Chief Business officer of Autifony, where she is responsible for strategic partnering, fundraising and commercial aspects of drug development for CNS disorders. In December 2017 Autifony signed a major collaboration with Boehringer Ingelheim. Barbara was also Chair of Puridify, a UCL spin-out with a breakthrough biotherapeutics purification technology, which was acquired by GE in November 2017. She chairs the LifeArc Seed Fund investment committee, and is on the Cambridge Enterprise Seed Fund Investment Committee. Previously, Barbara was CEO of Stabilitech, and she was Commercial Director at Arrow Therapeutics until the company was acquired by AstraZeneca. Barbara was also Senior Business Development Manager at Celltech. Barbara has a BA and D Phil in Chemistry from the University of Oxford, and is a Sloan Fellow from London Business School. Steve Bates, OBE CEO, BioIndustry Association Since his appointment as Chief Executive of the BioIndustry Association in 2012, Steve has led major BIA campaigns for, amongst other things, improved access to finance, the refilling of the Biomedical Catalyst, anti-microbial resistance and the opportunity the sector presents to generalist long term investors. Steve champions the adaptive pathway approach to the licensing of new drugs, the need for Early Access and is particularly proud of the working relationship the BIA has established with the UK’s leading medical research charities.
    [Show full text]
  • Guidelines with Regard to the Composition, Calculation and Management of the Index
    INDEX METHODOLOGY Solactive Pharma Breakthrough Value Index Version 2.1 dated September 03, 2020 Contents Important Information 1. Index specifications 1.1 Short Name and ISIN 1.2 Initial Value 1.3 Distribution 1.4 Prices and Calculation Frequency 1.5 Weighting 1.6 Index Committee 1.7 Publication 1.8 Historical Data 1.9 Licensing 2. Composition of the Index 2.1 Selection of the Index Components 2.2 Ordinary Adjustment 2.3 Extraordinary Adjustment 3. Calculation of the Index 3.1 Index Formula 3.2 Accuracy 3.3 Adjustments 3.4 Dividends and other Distributions 3.5 Corporate Actions 3.6 Correction Policy 3.7 Market Disruption 3.8 Consequences of an Extraordinary Event 4. Definitions 5. Appendix 5.1 Contact Details 5.2 Calculation of the Index – Change in Calculation Method 2 Important Information This document (“Index Methodology Document”) contains the underlying principles and regulations regarding the structure and the operating of the Solactive Pharma Breakthrough Value Index. Solactive AG shall make every effort to implement regulations. Solactive AG does not offer any explicit or tacit guarantee or assurance, neither pertaining to the results from the use of the Index nor the Index value at any certain point in time nor in any other respect. The Index is merely calculated and published by Solactive AG and it strives to the best of its ability to ensure the correctness of the calculation. There is no obligation for Solactive AG – irrespective of possible obligations to issuers – to advise third parties, including investors and/or financial intermediaries, of any errors in the Index.
    [Show full text]
  • Feasibility and First Reports of the MATCH-R Repeated Biopsy Trial At
    www.nature.com/npjprecisiononcology ARTICLE OPEN Feasibility and first reports of the MATCH-R repeated biopsy trial at Gustave Roussy Gonzalo Recondo 1, Linda Mahjoubi2, Aline Maillard3, Yohann Loriot1,4, Ludovic Bigot1, Francesco Facchinetti1, Rastislav Bahleda2, Anas Gazzah2, Antoine Hollebecque2, Laura Mezquita4, David Planchard1,4, Charles Naltet4, Pernelle Lavaud4, Ludovic Lacroix1,5,6, Catherine Richon5, Aurelie Abou Lovergne7, Thierry De Baere8, Lambros Tselikas8, Olivier Deas9, Claudio Nicotra2, Maud Ngo-Camus2, Rosa L. Frias1, Eric Solary10, Eric Angevin2, Alexander Eggermont4, Ken A. Olaussen1, Gilles Vassal7, Stefan Michiels 3, ✉ Fabrice Andre 1,4, Jean-Yves Scoazec5,6, Christophe Massard1,2, Jean-Charles Soria1,4, Benjamin Besse1,4 and Luc Friboulet 1 Unravelling the biological processes driving tumour resistance is necessary to support the development of innovative treatment strategies. We report the design and feasibility of the MATCH-R prospective trial led by Gustave Roussy with the primary objective of characterizing the molecular mechanisms of resistance to cancer treatments. The primary clinical endpoints consist of analyzing the type and frequency of molecular alterations in resistant tumours and compare these to samples prior to treatment. Patients experiencing disease progression after an initial partial response or stable disease for at least 24 weeks underwent a tumour biopsy guided by CT or ultrasound. Molecular profiling of tumours was performed using whole exome sequencing, RNA sequencing and panel sequencing. At data cut-off for feasibility analysis, out of 333 inclusions, tumour biopsies were obtained in 303 cases (91%). From these biopsies, 278 (83%) had sufficient quality for analysis by high-throughput next generation sequencing (NGS). All 278 samples underwent targeted NGS, 215 (70.9%) RNA sequencing and 222 (73.2%) whole 1234567890():,; exome sequencing.
    [Show full text]
  • Disclosure of Financial Relationships April 10-15 • May 17-21
    DISCLOSURE OF FINANCIAL RELATIONSHIPS APRIL 10-15 • MAY 17-21 In compliance with the standards set by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of the American Association for Cancer Research (AACR) that the information presented at CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, the AACR has pro- vided information that planning committee members, speakers, and abstract presenters have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity. Relationships are abbreviated as follows: E, Employee of listed company, G, Grant/research support recipient, A, Advisor or review panel member, C, Consultant, S, Stock Share- holder, SB, Speakers’ Bureau, H, Honoraria, O, Other. Last Name First Name Company Relationships Type Role Abate-Shen Cory NY Presbyterian Hospital Herbert Irving Comp. No Relationships Speaker Cancer Center Abdulkadir Sarki Northwestern University No Relationships Speaker Acharyya Swarnali Columbia University No Relationships Speaker Achilefu Samuel Washington University School of Medicine Sarya LLC; Integro Theranostics LLC C,O Speaker Adalsteinsson Viktor Broad Institute of MIT and Harvard Bertis Inc; AGCT GMBH A Speaker Adamopoulos Christos Icahn School of Medicine at Mount Sinai No Relationships Speaker Adamson Peter Sanofi Sanofi; AbbVie; Gilead; McKesson E,S Program Committee Agrawal Sundeep
    [Show full text]
  • Supergen, Inc. Changes Name to Astex Pharmaceuticals, Inc., Announces New Stock Ticker Symbol and New Website
    SuperGen, Inc. Changes Name to Astex Pharmaceuticals, Inc., Announces New Stock Ticker Symbol and New Website DUBLIN, Calif.--(BUSINESS WIRE)-- SuperGen, Inc. (NASDAQ:ASTX) announced that it has officially begun operating under the name Astex Pharmaceuticals, Inc. Concurrent with this new name, and effective at the start of trading today, September 12, 2011, the ticker symbol for the Company's common stock listed on NASDAQ has changed from "SUPG" to "ASTX." Astex Pharmaceuticals also announced the launch of its new website, www.astx.com. The website features the newly launched corporate branding, and contains information on the company's vision, pipeline and strategic partnerships. "We are extremely pleased to embark on a new era in our company's history," said James S.J. Manuso, Ph.D., chairman and chief executive officer of Astex Pharmaceuticals. "We now have the resources and capabilities in place to establish Astex Pharmaceuticals as a financially strong global leader with the aim of delivering novel cancer therapeutics targeting critical medical needs." Headquartered in Dublin, California, Astex Pharmaceuticals is dedicated to becoming a leader in the discovery, development and commercialization of a new generation of small molecule drugs, with a focus on cancer. With unrestricted cash, cash equivalents and current and non-current marketable securities of nearly $129 million as of June 30, 2011, the company plans to leverage its royalty revenue stream from Dacogen® (decitabine) for Injection, marketed in North America by Eisai and in the rest of the world by Cilag GmbH International, a wholly-owned subsidiary of Johnson & Johnson. The Company's clinical pipeline includes eight drugs in development, four of which are currently in or entering into Phase II clinical trials, and four of which are currently partnered or optioned to large pharmaceutical companies.
    [Show full text]
  • Expert Connect All Relationships Are Considered Compensated
    Expert Connect All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution Stock and Other Travel, Consulting or Advisory Speakers' Patents, Royalties, Other Expert Other Name Employment Leadership Ownership Honoraria Research Funding Accommodations, Role Bureau Intellectual Property Testimony Relationship Interests Expenses Brian M. Alexander Abbvie, Bristol-Myers Squibb, Precision Health Economics, Schlesinger Associates Nancy N. Baxter Harold J. Burstein Warren A. Chow Novartis Novartis (Inst) Don S. Dizon InfiniteMD Fuji Pharma, Pfizer, Aeterna Zentaris (Inst), UpToDate Bristol-Myers Squibb (Inst) Andrew S. Epstein UpToDate Patricia A. Ganz Intrinsic Abbott Laboratories, Biogen (I) InformedDNA, Keryx (I), Keryx (I) Related to iron metabolism Intrinsic LifeSciences LifeSciences (I) GlaxoSmithKline, Lilly, Merganser Biotech (I), and the anemia of chronic (I), Keryx (I) Intrinsic Silarus Therapeutics (I), disease (I), UpToDate LifeSciences (I), Vifor Pharma (I) royalties for section editor Johnson & Johnson, on survivorship Merck, Merganser Biotech (I), Novartis, Pfizer, Silarus Therapeutics (I), Teva, Xenon Pharma (I) Timothy D. Gilligan WellPoint David L. Graham Medscape Medscape Biopeps Daniel F. Hayes InBiomotion, Lilly AstraZeneca (Inst), Royalties from licensed Janssen Diagnostics OncImmune Janssen Research & technology; Diagnosis and Development (Inst), Lilly Treatment of Breast (Inst) Merrimack Cancer, Applicant Pharmaceuticals, Parexel Proprietor: University of Intl Corp (Inst), Pfizer Michigan, Dr. Daniel F. (Inst), Puma Biotechnology Hayes is designated as (Inst) inventor/co-inventor; Circulating Tumor Cell Capturing Techniques and Devices, Applicant Proprietor: University of Michigan, Dr. Daniel F. Hayes is designated as inventor/co-inventor; A method for predicting progression free and overall survival at each follow-up timepoint during therapy of metastatic breast cancer patients using circulating tumor cells.
    [Show full text]
  • Biocentury the BERNSTEIN REPORT on BIOBUSINESS
    WEEK OF SEPTEMBER 9, 2013 BioCentury THE BERNSTEIN REPORT ON BIOBUSINESS Volume 21 • Number 34 • Page A1 of 22 Regulation Breakthrough encore By Steve Usdin BioCentury This Week Washington Editor Friends of Cancer Research, the Cover Story which are prescribed off label for the condi- advocacy organization that conceived of tion./A13 and persuaded Congress to enact FDA’s Breakthrough Encore — Friends of breakthrough therapies program, last week Cancer Research is trying to create a Regulation unveiled a proposal to expedite develop- breakthrough diagnostics program to ensure ment of companion diagnostics that are companion Dx are ready when breakthrough Better Decisions Post-Avandia — Three intended for use with a breakthrough therapies are approved. While FDA agrees in cardiologists have asked FDA to ease its CV drug. principle, it warns money could be an issue. requirements on diabetes drugs in the aftermath In contrast to the breakthrough thera- of Avandia. But the bigger question is how FDA pies program, which was incorporated Strategy will react to the next post-market crisis./A14 into the FDA Safety and Innovation Act, FOCR’s new proposal focuses on steps Setting Amgen’s Targets — Acquiring Onyx Finance the agency and diagnostics companies can will more than double the bellwether’s portfolio take to streamline development and re- of marketed targeted cancer therapies, and puts Amgen’s Poker Face — SEC filings show view within existing law. it into a tie with GSK for second place behind Amgen shaved more than $400 million off the Senior agency officials, including Jef- Roche/Genentech. But it has to execute./A5 sticker price for Onyx after Kyprolis failed to frey Shuren, director of the Center for meet the early stopping criteria in the Phase III Devices and Radiological Health (CDRH), Product Discovery & Development FOCUS trial during negotiations./A16 and Janet Woodcock, director of the Cen- Ebb & Flow — Argos takes E round in the ter for Drug Evaluation and Research Checkpoint Complementarity — hand vs.
    [Show full text]
  • Conference Handbook 2013
    genesis Conference Handbook 2013 2013 WELCOME TO EDINBURGH BIOQUARTER Designed to foster scientific creativity and encourage entrepreneurship among clinicians and researchers, BioQuarter combines world-class research from EDINBURGH LAUNCHES WORLD’S FIRST Edinburgh University’s College of Medicine and Veterinary Medicine with the long tradition of clinical VISUAL FIELD ANALYSER FOR CHILDREN excellence at NHS Lothian. Building one of Europe’s most In March 2012, Edinburgh significant concentrations of clinical and research assets, BioQuarter launched i2eye Diagnostics Limited, creators BioQuarter brings together a major teaching hospital, of the world’s first visual field medical school and three leading research institutes in analyser for children and hard- one location. Our seasoned business development team to-test patient groups. Based on research undertaken at the has spun out four new businesses and negotiated four University of Edinburgh and major industrial collaborations in less than two years, as NHS Lothian, this device enables well as generating 100 new product or business concepts young children’s field of vision to from its innovation competition. be tested accurately for the first the company has booked its first time, helping to pick up retinal orders and is set to take premises and optic nerve defects as well in our new incubator building, To find out more about how this commercialisation as certain forms of brain cancer. Nine the BioQuarter: partnership is building on Scotland’s successes Backed by private venture capital, www.i2eyediagnostics.com in life sciences, visit www.bioquarter.com Sponsors 3 Genesis 2013 Sponsors Contents Gold Sponsors Welcome 7 Keynote Speakers 8 - 9 Speaker Profiles 9 - 21 Programme 22-23 Floor Plan 24 Exhibitor List 25 Silver Sponsors The Genesis Talent Lounge 27 Exhibitor Profiles 31- 42 ON Hub 43 Corporate Patron Bronze Sponsors Corporate Sponsors Case Study Sponsors Partners Supporters Wifi Sponsor Media Partners Scotland.
    [Show full text]
  • Astex Achieves Milestones in GSK Collaboration
    Astex Achieves Milestones in GSK Collaboration Cambridge, UK, 3rd May 2011. Astex Therapeutics, the UK-based biotechnology company developing targeted therapies for oncology and virology, announced that it has achieved multiple early milestones in its fragment-based drug discovery collaboration with GlaxoSmithKline which commenced in November 2009. Total milestone payments received under the collaboration have now reached £5.9 million. The milestones relate to the application of Astex’s Pyramid™ fragment based screening platform, against a number of molecular targets of interest to GSK. Following the identification of validated fragment hits, the joint project teams prioritise fragments to be taken into lead optimization with the intention of selecting clinical development candidates for further development by GSK. Commenting on the achievement of the early milestones, Dr Harren Jhoti, Astex’s Chief Executive Officer said, “We are delighted to have achieved these initial milestones within 18 months of beginning our collaboration with GSK. This achievement is testament, not only to the power of Astex’s technology to rapidly deliver novel chemical start points against challenging disease targets, but is also a reflection of how well the Astex-GSK joint project teams are working together in the collaboration. -ends- For more information, please contact: Astex Therapeutics Ltd Jeremy Carmichael, PhD Director of Business Development Tel: +44(0)1223 226200 Email: [email protected] Press & Media Enquiries College Hill (Europe) Melanie Toyne Sewell / Daniel Gooch Tel: +44 20 7866 7866 (US) Rebecca Skye Dietrich Tel: +1 857 241 0795 Email: [email protected] About Astex Therapeutics Astex is a UK-based biotechnology company that discovers and develops novel small molecule therapeutics.
    [Show full text]
  • 2020 Medicines in Development ꟷ Cancer
    2020 Medicines in Development ꟷ Cancer Product Name Sponsor Indication Development Status 177-Lu-edotretide ITM Solucin neuroendocrine tumors Phase III (peptide receptor radionucleotide Munich, Germany www.itm-radiopharm.com therapy) 177-Lu-NeoB Advanced Accelerator Applications solid tumors Phase I (radioligand therapy target GRPR) Millburn, NJ www.adacap.com 177-Lu-PSMA-617 Advanced Accelerator Applications metastatic castration-resistant Phase III (targeted radioligand therapy) Millburn, NJ prostate cancer www.adacap.com 177-Lu-PSMA-R2 Advanced Accelerator Applications prostate cancer Phase I (radioligand therapy target PSMA) Millburn, NJ www.adacap.com 2X-121 Oncology Venture US metastatic breast cancer, Phase II (PARP inhibitor) Scottsdale, AZ advanced ovarian cancer www.oncologyventure.com 609A 3SBio solid tumors Phase I (anti-PD1 antibody) Shenyang, China www.3sbio.com 67Cu-SARTATE™ Clarity Pharmaceuticals neuroblastoma Phase I/II (peptide receptor radionuclide Sydney, Australia www.claritypharmaceuticals.com therapy) Medicines in Development: Cancer ǀ 2020 1 Product Name Sponsor Indication Development Status 7HP349 7 Hills Pharma solid tumors Phase I (VLA-4/LFA-1 activator) Houston, TX www.7hillspharma.com 9-ING-41 Actuate Therapeutics myelofibrosis Phase II (GSK-3β inhibitor) Fort Worth, TX www.actuatetherapeutics.com ORPHAN DRUG advanced cancers, Phase I refractory malignancies (pediatric) www.actuatetherapeutics.com A166 KLUS Pharma HER2-expressing solid tumors Phase I (antibody-drug conjugate) Cranbury, NJ www.kluspharma.com
    [Show full text]
  • Translating UK Scientific Excellence Into Global Therapeutic Strategies Partnering for Scientifi C Leadership
    Conference Handbook 2014 Translating UK scientific excellence into global therapeutic strategies Partnering for scientifi c leadership astrazeneca.com/partnering 3618_Partnering_Ad_2013_A4.indd 1 27/09/2013 15:43 sponsors 3 ON Helix 2014 Sponsors contents Platinum Sponsors Welcome 4 Advisory Board 6-7 Keynote Speaker and VIP Panel 8-9 Agenda 10 Sponsors Floor Plan 11 Speaker Profiles 12-16 Exhibitors List 18-19 Supporters Corporate Patron Corporate Sponsors Media Partners Partners Media Partners 4 introduction welcome Dear ON Helix Participant, Welcome to our translational research Conference: ON Helix. Harriet Fear One of the key issues described Sir Mike Rawlins followed up by CEO, One Nucleus by many researchers is how to declaring it ‘THE translational event in overcome the innovation gaps on the the UK – it’s terrific’. So we decided to translational research pathway. This make it an annual fixture. includes identifying barriers on which to concentrate, finding funding and You can expect stimulating keynote meeting the right networks. speeches, exceptional world class case study examples of collaborations These topics are of course covered and technologies and plenty of by many conferences, but with ON networking. Helix, One Nucleus brings together all these elements in one event under The One Nucleus team and I one roof for one day. Excellence in know you will make full use of the translational research is a core skill presentations, debate, networking of many One Nucleus members and and the exhibitions to catch up with it seemed entirely appropriate that old friends and make some new ones, we should showcase that excellence update yourselves on trends in the to the UK and wider community; sector and create and scope out new especially if it will stimulate and business opportunities.
    [Show full text]
  • Biotech in Europe Investor Forum
    WELCOME PHARMA LICENSING GROUPS 12th Annual BIOTECH IN EUROPE SPEAKERS INVESTOR FORUM 1st-2nd October 2012 PRESENTING COMPANIES Hilton Zurich Airport Hotel, Switzerland Conference Guide SUPPORTING ORGANISATIONS SUPPORTING ORGANISERS www.sachsforum.com BIOTECH IN EUROPE INVESTOR FORUM WELCOME next u Welcome PHARMA LICENSING Sachs Associates are delighted to welcome you to the: 12th Annual Biotech in Europe GROUPS Investor Forum 1st-2nd October 2012 Hilton Zurich Airport Hotel, Switzerland Sachs Associates are delighted to welcome you to the 12th Annual Biotech in Europe Investor SPEAKERS Forum. Following the success of previous years, the forum once again provides access to an exciting cross-section of venture-funded and small-cap companies with leading investors and pharmas. This Forum is highly transactional and is comprised of a series of panels and presentations from leading investment, pharmaceutical and biotech companies, each one providing an expert outlook on growth and investment activity in Europe’s Biotech industry. The programme highlights the current issues surrounding the evolving M&A market, the Private PRESENTING COMPANIES Equity & Venture Capital environment and a special session on major trends in Partnering. Plus, this year’s programme features more than 70 company presentations from a range of publicly listed and private life science companies looking to raise finance and/or find partners. General Information The registration desk will be open from 8am on October 1st and from 8.15am on October 2nd although you are welcome to join the event at any time. Please collect a copy of the agenda for information on timing and room allocation for each session.
    [Show full text]